NOVAAGRINSENova Agritech Limited· Fertilizers & AgrochemicalsHighNegative
Announced Mon, 23 Feb, 2026 · 18:42 IST

Nova Agritech Limited has informed the Exchange about Credit Rating- Revision

Rating Watch NegativeCredit & Debt View source PDFExplain this filing

NOVAAGRI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+0.4%Reaction day
₹30.00
prior close
₹30.33
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-1.3%+1.7% vs market
Fertilizers peers, median of 19sector-0.8%+1.2% vs sector

On the reaction day the stock moved 1.7 pts more than Nifty Microcap 250 and 1.2 pts more than its Fertilizers peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-0.7
10m
-0.4
15m
-0.4
30m
-0.6
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+0.4-1.3+1.7-0.8+1.2
Next day
-1.3-1.1-0.2-0.1-1.2
2d
-1.5-0.8-0.6-0.5-1.0
3d
-0.7-1.9+1.2-1.0+0.3
4d
-5.3-4.1-1.2-3.8-1.4
5d
-8.7-6.6-2.0-7.3-1.4
1w
-7.0-5.7-1.2-8.2+1.2
15d
-10.6-6.4-4.2-6.6-4.0
1m
-29.0-9.9-19.1-11.6-17.4
2m
-5.3+3.8-9.2+0.4-5.7
3m
-4.6+8.9-13.5+2.2-6.8
UpDownMarket · Nifty Microcap 250Sector · Fertilizers peers, median of 19Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

CARE Ratings has reaffirmed Nova Agritech's long-term credit rating at CARE BBB but revised the outlook from 'Stable' to 'Negative' for both the company and its wholly-owned subsidiary Nova Agri Sciences Private Limited, covering facilities of about ₹31 crore (NAL) and ₹20 crore (NASPL). The revision is driven by a sharp Q3FY26 performance dip — income fell 25% sequentially and 28% year-on-year, hit by a government ban on bio-stimulants (about 30% of revenue) and prolonged monsoon in South and West India. Liquidity has turned stretched, with receivables of ₹214 crore (55% over six months old), inventory at ₹95 crore, and cash credit utilisation around 96%, pushing reliance on working capital borrowings. On the positive side, NAL received 43 product approvals in January 2026 which should help revive bio-stimulant sales, and the company has asked CARE to reconsider the rating.

Likely market impact

Negative outlook signals possible downgrade if liquidity doesn't improve, but the rating itself (BBB, investment grade) is unchanged. Shareholders should watch for working capital recovery and next quarter sales performance, as further deterioration could trigger an actual rating cut and higher borrowing costs.